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Spontaneous activation enables the complement system to
respond very rapidly to diverse threats. This activation is effi-
ciently suppressed by complement factor H (CFH) on self-sur-
faces but not on foreign surfaces. The surface selectivity of CFH,
a soluble protein containing 20 complement-control protein
modules (CCPs 1–20), may be compromised by disease-linked
mutations. However, which of the several functions of CFH
drives this self-surface selectivity remains unknown. To address
this, we expressed human CFH mutants in Pichia pastoris.
We found that recombinant I62-CFH (protective against age-
related macular degeneration) and V62-CFH functioned equiv-
alently, matching or outperforming plasma-derived CFH,
whereas R53H-CFH, linked to atypical hemolytic uremic syn-
drome (aHUS),was defective inC3bBbdecay-accelerating activ-
ity (DAA) and factor I cofactor activity (CA). The aHUS-linked
CCP 19 mutant D1119G-CFH had virtually no CA on (self-like)
sheep erythrocytes (ES) but retained DAA. The aHUS-linked
CCP 20 mutant S1191L/V1197A-CFH (LA-CFH) had dramati-
cally reduced CA on ES but was less compromised in DAA.
D1119G-CFH and LA-CFH both performed poorly at prevent-
ing complement-mediated hemolysis of ES. PspCN, a CFH-
binding Streptococcus pneumoniae protein domain, binds CFH
tightly and increases accessibility of CCPs 19 and 20. PspCNdid
not improve the DAA of any CFH variant on ES. Conversely,
PspCN boosted the CA, on ES, of I62-CFH, R53H-CFH, and LA-
CFH and also enhanced hemolysis protection by I62-CFH and
LA-CFH.We conclude that CCPs 19 and 20 are critical for effi-
cient CA on self-surfaces but less important for DAA. Exposing
CCPs 19 and 20 with PspCN and thus enhancing CA on self-
surfaces may reverse deficiencies of some CFH variants.
The complement system provides antibody-independent
first-line immune defense. It also augments antibody-mediated
and cellular immunity (1). In addition, complement contributes
to clearance of by-products of cellular metabolism and cell
turnover (2). The cleavage of C3, a thioester-containing serum
protein, into C3a and C3b, is pivotal to all three pathways
of complement activation. In the alternative pathway, C3 is
cleaved byC3bBb, a short-lived complex ofC3b andBb, a serine
protease. In aMg2-dependent process, C3bBb-generated C3b
binds to complement factor B (CFB),3 a proenzyme,whereupon
CFB is cleaved by complement factor D (CFD) to yield more
C3bBb. Thus, a C3b amplification loop is generated (3) (Fig.
1A). Transiently, nascent C3b can utilize its freshly activated
thioester to covalently attach to surfaces (4). Here, unless
regulated, C3b is amplified, forms clusters, functions as an
opsonin, and triggers further steps in the complement cascade,
including C5 cleavage, C5a release, and formation of mem-
brane attack complexes.
A set of plasma proteins calibrates C3b amplification. Pro-
perdin (5) stabilizes C3bBb, whereas complement factor H
(CFH) (6–8) (Fig. 1B) destabilizes it; this is called decay-accel-
erating activity (DAA). CFH also has cofactor activity (CA) for
cleavage of C3b by complement factor I (CFI). The product,
iC3b, cannot bind CFB but is an opsonin in its own right (9).
iC3b may be further degraded to C3dg and, ultimately, to C3d.
C3d(g) remains covalently bound to the surface for an extended
period of time and thereby marks sites of historical comple-
ment activation and regulation. As a soluble circulating com-
plement regulator, CFH suppresses spontaneous complement
activation in fluid phase that is considered “futile” and that con-
sumes C3 and factor B. Critically, CFH efficiently suppresses
C3b amplification on self-surfaces (10) but not on foreign ones.
Other host complement regulators (11), which also exhibit
DAA and/or CA, are permanently attached to cell surfaces.
Together, the complement regulators ensure that the opsoniz-
ing, inflammatory, and cytolytic consequences of complement
This work was supported in part by the Leverhulme Trust (RPG-2015-109)
and by Biotechnology and Biological Sciences Research Council Grant
BB/024403/1. A. P. H. and P. N. B. are consultants for, and scientific found-
ers of, Gemini Therapeutics.
Author’s Choice—Final version free via Creative Commons CC-BY license.
1 A Medical Research Council Clinical Training Fellow.
2 To whom correspondence should be addressed: School of Chemistry,
Joseph Black Bldg., University of Edinburgh, David Brewster Rd., Edin-
burgh EH9 3FJ, Scotland, UnitedKingdom. Tel.: 44-0-131-650-4727; E-mail:
Paul.Barlow@ed.ac.uk.
3 The abbreviations used are: CFB, CFD, CFH, andCFI, complement factor B, D,
H, and I, respectively; aHUS, atypical hemolytic uremic syndrome; AMD,
age-related macular degeneration; C3G, C3 glomerulopathy; CA, cofactor
activity; CCP, complement-control protein module; C-FxD, complement-
fixation diluent; DAA, decay-accelerating activity; ER, rabbit erythrocytes;
ES, sheep erythrocytes; EAS, sensitized sheep erythrocytes; GAG, glyco-
saminoglycan; LA-CFH, S1191L/V1197A-CFH; NHS, normal human serum;
SA, sialic acid; PspCN, S. pneumoniae choline-binding protein, N-terminal
domain; SPR, surface plasmon resonance; CFHR, CFH-related protein; RU,
resonance units.
croARTICLE
Author’s Choice
J. Biol. Chem. (2017) 292(32) 13345–13360 13345
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
 at U
niversity of Edinburgh on Septem
ber 5, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
activation manifest on targets rather than on healthy self-sur-
faces. CFH-related proteins 1–5 (CFHR-1 to -5) (12) provide
additional regulatory sophistication. Some of them antagonize
CFH by competing with it for binding to targets including C3b
(13, 14).
Inherited variations in membrane cofactor protein (MCP,
CD46), CFB, C3, CFI, CFHRs, and, in particular, CFHare linked
to diseases (15, 16). Numerous disease-related sequence varia-
tions were identified in CFH, which consists exclusively of
20 complement-control protein modules (CCPs). The SNP,
H402Y, within the seventhCCP (CCP 7) is linked to age-related
macular degeneration (AMD) (17–20) and the kidney disorder,
C3 glomerulopathy (C3G) (21); H402 is the at-risk allele. The
SNP, I62V, in CFHCCP 1 is also linked to AMD (20, 22); Ile-62
is protective. Deletion of the CFHR-1 and CFHR-3 genes
decreases the risk of immunoglobulin A nephropathy and
AMD(23–26) but predisposes to systemic lupus erythematosus
and atypical hemolytic uremic syndrome (aHUS), a form of
thrombotic micoangiopathy leading to end-stage renal fail-
ure (27). Most mutations found in aHUS patients cluster in
the CFH C-terminal CCPs 19 and 20 (28). Other potentially
disease-linked sequence variations occur elsewhere in CFH
(29–31).
Penetrance is low for many of the CFH mutations linked to
diseases. Variation in the genes for other complement proteins
and environmental factors may also contribute to disease risk
(32). The complexity of complement modulation underlines
the need to explore functional effects of each potentially dis-
ease-causing CFH variant. However, the scarcity of pure CFH
samples is limiting (22, 33). Most patients are heterozygous for
mutations that occur on a polymorphic background. Recombi-
nant production of full-length CFH, a single polypeptide con-
taining 40 disulfides (two per CCP), is challenging (34–36). In
only one case (36) were yields sufficient for rigorous sample
authentication.
Many studies have tried to recapitulate disease-linked muta-
tions in more easily produced CFH truncations containing up
to five CCPs (37–42). Indeed, most disease-linked variations
occur within subsets of CCPs, namely CCPs 1–4, CCP 7, or
CCPs 19 and 20, which coincide with functional sites (43) (Fig.
1B). For example, a fragment consisting of CFH CCPs 1–4
(CFH 1–4) binds C3b and has CA (44) and DAA (45). CFH
19-20 has neither CAnorDAAbut bindsC3b, iC3b, andC3d(g)
(46). Recombinant CFH 6–8 and CFH 19-20 bind glycosami-
noglycans (GAGs) and sialic acids (SAs) found on self-surfaces
(47). Recombinant CFH 19-20 binds well to C3d and thereby
competes with full-length CFH for binding to C3b-decorated
sheep erythrocytes (ES) (37), whereas disease-relatedmutations
in CCPs 19 and 20 perturbed this ability (39).
Crucially, the use of small CFH truncations cannot capture
the collaboration between multiple binding sites that charac-
terizes CFH function in its biological setting. CFH probably
undergoes a conformational adjustment (48–50) in a concerted
process that involves engagement, via GAG-binding and SA-
binding sites in CCPs 7 and 20, with self-surface markers (43).
This is thought to allow theC3b/C3d(g)-binding sites located in
CCPs 1–4 and CCPs 19 and 20 (47) to engage simultaneously
with C3bmolecules bound on a host surface (50). Crucially, the
resultant CFH–C3b–GAG/SA complex is better at comple-
ment suppression than the CFH–C3b complex formed on a
surface lacking GAGs and SAs.Whether this enhanced efficacy
on self-surfaces is driven by higher DAA, higher CA, or both is
unknown. Recombinant full-length CFH is needed to investi-
gate these key self versusnon-self discriminatory properties and
to establish the phenotypic consequences of disease-related
mutations.
Herein, we illustrate the value of producing recombinant
full-length CFH for characterizing disease-linked sequence
variations. After benchmark work on substitutions in N-termi-
nal CCPs, we focused on potentially more revealing mutations
in C-terminal CCPs (Fig. 1B). We investigated the activities of
these CFH mutants on the man-made surfaces of surface plas-
mon resonance (SPR) chips and the foreign surface of rabbit
erythrocytes (ER) as well as on the more hostlike surface of ES.
We additionally investigated the functions of our mutants
when in complex with PspCN. PspCN is a domain from a bac-
terial complement evasion protein that binds very tightly to
CFH (51) and causes it to adopt a different conformation with
enhanced regulatory efficacy (50). Binding to CFH of PspCN
increases the accessibility of CCPs 19 and 20, as also probably
occurs when CFH binds to a self-surface. Our studies suggest
that CA, more than DAA, is boosted by interactions between
the C-terminal region of CFH and self-surfaces.
Results
High-yield production of CFH variants in P. pastoris
We produced the two common allotypic CFH variants with
Ile or Val at position 62 of the mature protein (I62-CFH or
V62-CFH, respectively) in recombinant P. pastoris. We also
produced the disease-related mutants, R53H-CFH (on Ile-62
background), D1119G-CFH (on Val-62 background), and
S1191L/V1197A-CFH (henceforth LA-CFH) (on Ile-62 back-
ground). TheP. pastoris-secreted proteinswere harvested prior
to endoglycosidase treatment to cleave mannose-rich and
hence non-native N-glycans back to the first GlcNAc residues.
Following purification, homogeneity was assessed using SDS-
PAGE (Fig. 1C). The absence of extra bands in the gel, under
both reducing and non-reducing conditions, indicates minimal
proteolytic cleavage. Note that cleavage within a CCP might
have been evident only in reduced samples due to the interlaced
disulfide bonds within each CCP (i.e.Cys(i) to Cys(iii) and Cys(ii)
to Cys(iv)) (52). All proteins were prepared in multiple 10-mg
quantities.
V62-CFH and I62-CFH have similar biological activities
We compared binding to C3b of I62-CFH, V62-CFH, and
CFH purified from human plasma (plasma CFH). Both recom-
binant protein samples were freshly produced, purified, and
assayed in parallel. The plasma CFH sample was purified from
pooled human plasma and contained no CFH-related proteins
detectable by Coomassie Blue-stained SDS-PAGE (Fig. 1C).
Aliquots were stored at20 °C. An aliquot was freshly thawed
for each experiment. The C3b sample (Complement Technol-
ogy, Tyler, TX) had been stored at80 °C and was also thawed
immediately before use. TheC3bwas immobilized on a Biacore
C1-sensor chip, using amine coupling. By flowing CFH solu-
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tions over amine-coupled C3b (Fig. 2, A and B), we obtained
similar KD values (in the range of 0.21–0.33 M) for all three
proteins (Table 1).
We also compared binding of these three versions of CFH to
C3d (Complement Technology) amine-coupled to a different
flow cell on the same C1-sensor chip as used for the C3b-bind-
ing experiments (Fig. 2, A and C). Both I62-CFH and V62-CFH
bound to immobilizedC3dwithKD values of1.9M (Table 1).
Conversely, binding of plasma CFH to C3d was, as observed
previously (13, 49, 50), too weak to measure (Fig. 2A). The lack
of binding between plasmaCFH andC3dwas previously attrib-
uted to lack of access to theC3d-binding site inCCPs 19 and 20.
Indeed, premixing 0.6 M plasma CFH with 1.2 M PspCN
transformed it into a C3d binder (Fig. 2D and Table 1), as seen
previously (50). Premixing I62-CFH or V62-CFH with PspCN
also enhanced their binding to both C3b and C3d (Fig. 2D and
Table 1). For confirmation, two additional SPR-based experi-
ments were performed on a different batch of I62-CFH, each on
a different daywith a different chip. In both experiments (Table
1), the KD of I62-CFH for C3b was approximately halved fol-
lowing preincubation (of I62-CFH) with a 2-fold molar excess
of PspCN. Thus, both plasma CFH and recombinant CFH bind
PspCN, via their central CCPs (50), and undergo a conforma-
tional change that renders the C-terminalmodulesmore acces-
sible to C3d.
In SPR-based assays on a CM5-sensor chip (Biacore), we
compared the abilities of recombinant and plasma CFH to
accelerate decay of the preassembled C3bBb, the alternative
pathway C3 convertase. Both I62-CFH and V62-CFH, at 20 nM,
had identicalDAA in this assay, whereas 20 nMplasmaCFHwas
less active (Fig. 3A). The presence of PspCN (at a 2:1 ratio to
CFH) enhanced theDAAof I62-CFHandV62-CFH to identical
extents (Fig. 3B). As expected, PspCN also enhanced the DAA
of plasma CFH in this assay.
Functional similarities between I62-CFH and V62-CFH
extended to hemolysis protection assays. Upon exposure to
increasing percentages of CFH-depleted normal human serum
(NHS), ES are susceptible to lysis by complement unless pro-
tected by added CFH. ER, in contrast, lack human-like SAs and
are not effectively protected by humanCFH. Both I62-CFH and
V62-CFH proved equally effective (e.g. at 250 nM) in preventing
ES hemolysis (Fig. 4A) in this assay, whereas both were, as
expected, equally ineffective, at 1M, in protecting ER (Fig. 4B).
Both I62-CFH andV62-CFH showedmore ability to preventER
hemolysis when in complex with PspCN.
In a more specific Es-surface assay (22), C3bBb was preas-
sembled on ES, and the resultant C3bBb-decorated cells were
exposed to a CFH concentration series. This was followed by an
assay of surviving C3bBb, thus allowing estimation of an IC50
value for DAA on a “hostlike” cell surface. Both I62-CFH and
V62-CFHexhibited an IC50 of1.3 nM in this assay (Fig. 5A and
Table 2). In a related study, ES surfaces were preloaded with
C3b and then treated with CFI and a CFH concentration series.
The remaining C3b was estimated in a hemolysis assay, as
before. This provided an IC50 for the CA of CFH on a surrogate
self-surface. In this assay, both I62-CFH (IC50  8.0 nM) and
V62-CFH (IC50  9.5 nM) had similar potencies (Fig. 5B and
Table 2). The effect of PspCN in both of these assays was
explored for I62-CFH. Unexpectedly, I62-CFH alone and
I62-CFH–PspCN complex had indistinguishable DAA on ES-
bound C3bBb (Fig. 5C). Conversely, and interestingly, PspCN
improved the CA of I62-CFH on ES-bound C3b by a factor of 2
(Fig. 5D and Table 2).
In summary, I62-CFH and V62-CFH bound with similar
affinities to C3b and to C3d on SPR chips. They had nearly
identical DAA on this man-made “foreign” surface. In hemoly-
sis protection assays, both I62-CFH and V62-CFH protected
self-like ES, but neither protected the less self-like ER unless
PspCNwas present. PspCN enhanced binding of both I62-CFH
and V62-CFH to C3b and C3d on SPR chips, where it also
enhanced DAA. PspCN increased the CA, but not the DAA, of
CFH on ES.
A disease-linked CCP 1mutation has similar effects on
self-surfaces and foreign surfaces
The disease-linked R53H mutation in CFH CCP 1 was pre-
viously studied within recombinant CFH 1–4 (41). Although
R53Hdid not perturb binding ofC3b byCFH1–4, it did disrupt
both the CA and DAA of CFH 1–4 on ES. Here, we prepared
full-length R53H-CFH. In side-by-side comparisons, R53H-
CFH bound about as tightly as I62-CFH to amine-coupled C3b:
SPR-derived KD values of 1.2 M for I62-CFH and 1.8 M for
R53H-CFH (Fig. 6A and Table 1) in a first experiment and 1.0
and 1.2 M for I62-CFH and R53H-CFH, respectively, in a sec-
ond experiment (Table 1). In these two experiments, PspCN
Figure 1. CFH and its roles in regulating complement. A, amplification of
C3b via C3bBb. CFH accelerates irreversible decay of C3bBb and is a cofactor
for CFI that cleaves C3b to iC3b. B, schematic of CFH highlighting mutations
investigated in this study. CFH consists exclusively of 20CCPs, shownasovals.
C3b-binding sites (shaded) are located in N-terminal and C-terminal regions.
The C3b-binding site in CCPs 19 and 20 also binds iC3b, C3dg, and C3d; it is at
least partially cryptic and is exposed when CFH binds PspCN (P) (a domain
fromabacterial virulence factor) orwhenCFH is on a self-surface. Self-surface
recognition sites, which bind to GAGs and SAs, reside in CCPs 7 and 20. CCPs
1–4 are necessary and sufficient (in fluid phase) for DAA andCA. C, five degly-
cosylated recombinant proteins used herein (V62-CFH, I62-CFH, R53H-CFH,
D1119G-CFH, and LA-CFH) along with CFH purified from pooled plasma
(p-CFH) were subjected to SDS-PAGEunder both reducing (R) and non-reduc-
ing (NR) conditions and stained with Coomassie Blue.MW, molecular weight
markers.
Disease-linkedmutations in recombinant factor H
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(2:1molar ratio to R53-CFH) enhanced binding toC3b from1.8
to 1.0 M or from 1.0 to 0.6 M, respectively. This is a PspC-
induced gain similar to that seen for I62-CFH (Table 1).
Despite their similar affinities for C3b, R53H-CFH (at 40 nM)
exhibited poorer DAA on a CM5-sensor chip (Fig. 6B) in com-
parison with 40 nM I62-CFH. Similarly, in assays of DAA per-
formed on C3bBb-decorated ES, R53H-CFH (IC50  6.6 nM)
performed less well than I62-CFH (IC50 1.4 nM) (Fig. 6C and
Table 2). In an assay on C3b-decorated ES, R53H-CFH (IC50
43 nM) was likewise less effective in CA than I62-CFH (IC50
18nM) (Fig. 6D). PspCN (2:1molar ratio toCFH) did not notice-
ably improve the DAA of R53H-CFHmeasured on ES (Fig. 6E).
A 2-fold ratio of PspCN to R53-CFH did improve its CA on ES
(Fig. 6F and Table 2).
These functional deficiencies of R53H-CFH were not imme-
diately evident in hemolysis protection assays. Although R53H-
CFH, with or without PspCN, did not protect foreign ER (Fig.
4D), it was able to protect the more “self-like” ES (Fig. 4C).
Figure 2. C3b and C3d binding of plasma-purified CFH, I62-CFH, and V62-CFH. All data shown here were collected in one SPR experiment on the same
C1-sensor chip. Care was taken to ensure that the CFH samples were all of equivalent quality and concentration. A, 2-fold dilution series (from 2.5 to 0.019M)
of CFH from plasma were flowed in duplicate over amine-coupled C3b (left) or C3d (right). Equilibrium plots were used in an attempt to estimate KD values
(Table 1), but no affinity measurement could be made for C3d (inset, background-subtracted sensorgrams). B, 2-fold dilution series (from 2.5 to 0.019 M) of
I62-CFH (left) or V62-CFH (right)were flowed induplicateover amine-coupledC3b, andKD valueswereestimatedas above. Two further experiments comparing
V62-CFHwith plasma CFH indicated similar binding to C3b. C, an equivalent set of experiments to B butwith C3d instead of C3b.Multiple replicates confirmed
the discrepancy in C3d binding between recombinant CFH and plasma CFH.D, sensorgrams for I62-CFH, V62-CFH, or plasma CFH (p-CFH) all at 0.6M, with or
without PspCN (at 1.2M), flowed over C3b (left) or C3d (right). Very similar PspCN-induced enhancements of both plasma CFH and recombinant CFH binding
to C3b and C3d were observed in multiple experiments; KD values were estimated for I62-CFH alone versus I62-CFH–PspCN complex (see Table 1).
Disease-linkedmutations in recombinant factor H
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Protection of ES in this case may reflect the inability of R53H-
CFH to prevent turnover and hence “futile” depletion of C3 in
the fluid phase, yet a 1:1 mixture of R53H-CFH with I62-CFH,
included in an effort to prevent fluid-phase C3 depletion, was
likewise protective in this assay (Fig. 4E). By competing with
I62-CFH for binding to soluble C3b, R53H-CFH might antag-
onize the fluid-phase C3-conserving regulatory action of I62-
CFH. In a further investigation of this phenomenon, R53H-
CFH was mixed 1:1 with the S1191L/V1197A-CFH (LA-CFH)
mutant. As described below, LA-CFH prevents C3 depletion in
fluid phase, although it exhibits impaired binding to SA-deco-
rated surfaces. The R53H-CFH/LA-CFH mixture was less able
to prevent ES hemolysis than R53H-CFH alone (Fig. 4E). This is
consistent with non-depletion of C3, an expected consequence
of the fluid-phase regulatory action of LA-CFH. Importantly, it
confirms the lack of ability of either LA-CFH or R53-CFH, for
different reasons, to fully control C3b amplification on the ES
surface.
To summarize, R53H-CFH is functionally deficient despite
retaining good affinity for C3b. The inability of R53H-CFH to
regulate C3b amplification on ES is consistent with its poor ES
hemolysis protection properties under circumstances where
fluid-phase C3 levels are not depleted.
Perturbation of the C-terminal C3b/d-binding site
Asp-1119 of CCP 19 is a key interface residue in the CFH
19-20–C3d complex (53). In recombinant CFH 19-20, D1119G
abrogated binding to C3b and C3d (39, 53) and destroyed the
ability to compete with plasma CFH for binding to C3b-deco-
rated ES (37, 39). In full-length CFH, D1119G was previously
shown to degrade performance in ES hemolysis protection
assays (50). To explore further the functional consequences of
D1119G in full-length CFH and allow comparisons with the
other CFH mutants reported herein, we measured separately
the DAA and CA of D1119G-CFH on ES. As shown in Fig. 7A
and Table 2, the ability of D1119G-CFH to accelerate decay of
C3bBb on ES was diminished compared with wild-type CFH
(IC50  1.3 nM for I62-CFH versus IC50  11 nM for D1119G-
CFH). The negative effect of D1119G on the CA of CFH for
cleavage of C3b bound to ES is greater still (IC50  12 nM for
I62-CFH versus IC50  500 nM for D1119G-CFH) (Fig. 7B).
PspCN (at a 2:1 molar ratio to D1119G-CFH) had negligible
effects on the C3bBb-DAA (Fig. 7C) and C3b-CA of D1119G-
CFH measured on ES (Fig. 7D).
Perturbation of the sialic acid-binding site in CCP 20
Ser-1191 and Val-1197 in CCP 20 are critical for recognition
of SA according to a crystal structure of a C3d–CFH 19-20–SA
complex (54). In previous work, the disease-related double
Table 1
Summary of SPR data
Experiment Variant Ligand
Without PspCN With PspCN
KD (M)a Rmax Roffset 2 KD (M) Rmax Roffset 2
I62-CFH versus V62-CFH versus plasma CFH I62-CFH C3b 0.21 0.02 79.2 32.2 5.2
V62-CFH C3b 0.27 0.03 80.0 19.3 4.6
plasma-CFH C3b 0.33 0.02 59.6 8.0 0.6
I62-CFH C3d 1.8 0.2 50.6 0.5 0.3
V62-CFH C3d 2.1 0.2 52.2 0.0 0.2
plasma-CFH C3d high
I62-CFH versusmutants, with/without PspCN (Expt. 1)b I62-CFH C3b 1.2 0.2 175 34.8 5.2 0.50 0.07 266 63.5 31
R53H-CFH C3b 1.8 0.3 217 42.9 6.5 1.0 0.1 310 75.3 13
LA-CFH C3b 0.83 0.10 181 46.6 8.3 0.70 0.07 249 91.2 16
I62-CFH versusmutants, with/without PspCN (Expt. 2) I62-CFH C3b 1.0 0.2 117 41.2 4.0 0.62 0.08 132 55.6 5.8
R53H-CFH C3b 1.2 0.1 152 41.1 3.7 0.58 0.04 134 52.1 2.5
LA-CFH C3b 0.86 0.11 146 45.7 6.6 0.60 0.07 151 61.4 8.0
a Shown are the S.E. values for the fits of the data from each experiment.
b Expt., experiment.
Figure 3. Decay-accelerating activity of CFH on SPR sensor chips. A,
C3bBbwas formedon aCM5-sensor chip by flowingC3, CFB, andCFDover an
immobilized C3b “seed.” The C3bBb DAAs of 20 nM V62-CFH and 20 nM I62-
CFH were compared with that of 20 nM plasma CFH (p-CFH). B, these experi-
mentswere repeatedbutwith a 1:2mixture of CFHandPspCN (i.e. CFH:P). The
curve for I62-CFH from (A) (i.e. with no PspCN) is included for reference; note
that I62-CFH and plasma-derived CFH–PspCN (p-CFH:P) have overlapping
curves. The data shown are representative of an experiment performed four
times.
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mutation S1191L/V1197A perturbed the ability of CFH 19-20
to compete with full-length CFH for binding to C3b-decorated
ES (39, 53) but did not perturb the structure of CFH 19-20 nor
interfere with its binding,measured by SPR, to C3b or C3d (42).
Here, we found that the SPR-measured affinities of full-length
LA-CFH and I62-CFH for amine-coupled C3b are indeed sim-
ilar:KD 0.8M for LA-CFH versus 1.2M for I62-CFH in one
experiment (Fig. 8A) and 0.9 M for LA-CFH versus 1.0 M for
I62-CFH in a second experiment (Table 1). In these two exper-
iments, preincubation of LA-CFHwith PspCN in a 2-foldmolar
excess produced little if any gain in affinity for C3b (KD 0.70
M versus 0.83 M and KD  0.60 M versus 0.86 M, respec-
tively; Table 1). No effect of these mutations on the DAA of
full-length CFH, assayed on the SPR chip surface, could be
detected (Fig. 8B). Taken together, these results suggest that the
N-terminal region of CFH dominates its properties on the for-
eign surface of a SPR chip such that C-terminal mutations have
undetectable effects.
When assayed on hostlike ES cells, S1191L/V1197A had a
smaller effect on DAA than on CA (Fig. 8, compare C and D).
The effect on DAA was measurable but minor (IC50  1.6 nM
for I62-CFH versus IC50  2.9 nM for LA-CFH) (Fig. 8C and
Table 2), whereas in the CA assays, a larger effect was evident
(IC50  18 nM for IYD-CFH versus IC50  63 nM for S1191L/
V1197A-CFH) (Fig. 8D and Table 2). Thus, SA bindingmatters
less for DAA than it does for CA. Furthermore, we found that
LA-CFH affords significantly less protection than wild-type
CFH to ES in the hemolysis protection assay (Fig. 4C). As is
apparent from the results of further experiments on ES,
PspCN did not measurably increase the DAA of LA-CFH,
but it clearly enhanced the CA of LA-CFH (Fig. 8, compare E
and F), although the wild-type IC50 was not restored (Table
2). In ES hemolysis protection assays, the addition of PspCN
was, notably, able to partially rescue LA-CFH (Fig. 4C), just
as it had previously been found to partially rescue another
C-terminal mutant, D1119G-CFH (50). Moreover, PspCN
Figure 4. Erythrocyte-protection assays. ES or ER were incubated with CFH-depleted NHS at various percentages (v/v) that had been reconstituted with our
recombinant CFH variants. A, reconstitution with 250 nM I62-CFH or 250 nM V62-CFH afforded protection of ES, with or without 500 nM PspCN. B, neither 1 M
I62-CFH nor 1 M V62-CFH protected ER. PspCN (2 M) enhances CFH protection in both cases. C, LA-CFH (500 nM), unlike 250 nM I62-CFH, offered little
protectionagainst ES lysis. No lysis occurred in thepresenceof 250nMR53-CFH. Theadditionof 500nMPspCN to250nMLA-CFH (final concentrations) improved
its protective properties. D, neither 1 M LA-CFH (alone) nor 1 M R53-CFH (with or without 2 M PspCN) protected ER, but a mixture of 1 M LA-CFH 2 M
PspCNwasmore protective than LA-CFH alone. E, LA-CFH (500 nM) (unlike 500 nM I62-CFH) did not protect ES from lysis; nor did amixture of 250 nM LA-CFH
250 nM I62-CFH. Amixture of 250 nM R53H-CFH 250 nM I62-CFH was protective. A mixture of 250 nM R53H-CFH 250 nM LA-CFH wasmore protective than
500 nM LA-CFH alone but less protective than R53-CFH alone (see C). Six independentmeasurements weremade in B, whereas A and C–E are representative of
two independent experiments. Themean and S.D. (error bars) for eachmeasurementwere calculated for all data sets (inmost cases, error bars are obscured by
the symbol).
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also boosted the ability of LA-CFH to protect the foreign
surface of ER (Fig. 4D).
Discussion
Nearly 100 variations in the human CFH gene potentially
predispose to aHUS or other diseases (16, 31). Most encode
versions of CFH that differ by a single amino acid. Wild-type
CFH both inhibits fluid-phase C3 consumption and prevents
formation of clusters of deposited C3b molecules on selected
surfaces. Only a small fraction of the putatively disease-linked
versions of CFH have been functionally characterized in any
detail, and 75–80% have not been functionally characterized at
all (31). It is often impractical to purify sufficient CFH for rig-
orous functional analysis from a heterozygous patient. Aiming
at a fast and efficient means of obtaining tens of milligrams of
protein, we expressed CFH variants in P. pastoris.
A previously reported careful comparison between plasma-
purified versions of V62-CFH and I62-CFH provided a bench-
marking opportunity (22). Our yields of recombinant V62-CFH
and I62-CFH exceeded those of previous attempts to produce
CFH in mammalian (33), insect (34), and moss cells (35, 55).
Our versions of V62-CFH and I62-CFH differ in sequence at
position 936 as well as at position 62 (i.e. we compared
V62,E936-CFH with I62,D936-CFH). The E936D SNP is not
unique to at-risk or protective haplotypes (20) nor located near
binding sites (43) for C3b, C3d(g), or carbohydrates. Although
Asp-936 protects against susceptibility to meningococcal dis-
ease (56), this SNP is unlikely to impact our assays.
Figure5.Decay-acceleratingandcofactor activities of I62-CFHandV62-CFHonES.A, activated ESwerepreloadedwithC3bBb. TheC3bBb-decorated cells
were exposed to a CFH concentration series, followed by a hemolysis-based estimate of remaining C3bBb. This allowed derivation of IC50 values for DAA on a
hostlike cell surface. B, C3b-preloaded activated ES surfaces were treated with CFI and a range of CFH concentrations, providing an estimate of the CA of CFH
on a hostlike cell surface. C, the DAA assay used in A was repeated, but using I62-CFH mixed (1:2) with PspCN. The curve for I62-CFH alone is included for
comparison. D, the CA assay used in B was repeated, but using I62-CFH mixed (1:2) with PspCN. The curve for I62-CFH alone is included for comparison. The
mean and S.D. (error bars) of triplicate measurements are plotted, and sigmoidal curves were fitted using SigmaPlot. Each graph is representative of two
experiments, except for A and D, which show data from single experiments.
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Our recombinantV62-CFHand I62-CFHmatched function-
ally our plasmaCFH in our assays of C3b binding,DAA, andCA
(Figs. 2–5). Remarkably, however, recombinant V62-CFH and
I62-CFH bound very much better than plasma CFH to immo-
bilizedC3d (Fig. 2B). Our pooled plasma-derivedCFH contains
amixture of common haplotypic variants, but these are located
in CCPs 1, 7, and 15, so are unlikely to impact directly on C3d
binding that involves onlyCCPs 19 and 20. Contaminationwith
CFH-related proteins in the plasma CFH sample is unlikely
because these were removed during purification. Whereas
chemical modifications may be present in aging plasma pro-
teins (57), these would be unlikely to have such a drastic and
specific effect. The most likely explanation for the difference in
C3d binding between recombinant CFH and plasmaCFH is the
lack of N-glycans in recombinant CFH. Natural CFH (36, 58)
has eight of these. Some might contribute to the hidden or
cryptic nature of the C3d-binding site in CCPs 19 and 20 dis-
cussed previously (50).
I62-CFH bound marginally better than V62-CFH to C3b in
our SPR-based comparison using identically prepared samples
(Table 1), but more replicates would be required to afford
significance to this. In further SPR measurements, PspCN
enhanced C3b binding and the DAA of I62-CFH and of V62-
CFH to nearly identical extents. A slightly tighter complex with
C3b formed by I62-CFH was reported in an SPR study con-
ducted on plasma-derived CFH in reverse mode (i.e. C3b was
flowed over immobilized plasma CFH) (22) (KD values: Ile-62,
1.04 M; Val-62, 1.33 M). Comparisons of I62- and V62-CFH
are important because Ile-62 is encoded by an SNP unique to a
protective haplotype for AMD and C3G (20). A “complotype”
hypothesis (59) predicts that a coincidence of minor functional
effects in several complement proteins could be additive in a
patient. Our I62-CFH versus V62-CFH comparison also agrees
with the approximate parity of C3b binding between recombi-
nant Ile-62 and Val-62 variants of CFH 1–4 (41), despite CFH
1–4 binding C3b (KD 11–14 M) much less tightly than full-
length CFH.
Reported SPR-derived KD values for binding of CFH to C3b
vary severalfold (36, 49, 53), and the 0.2–0.3 M KD values
obtained in our three-way comparison are at the tighter end of
the range. In other experiments (Table 1), we obtained weaker
KD values, in the 1.0–1.3M range, for the same I62-CFH sam-
ple. We have, over numerous previous experiments, noticed
such variations between SPR-derived KD values. These proba-
bly reflect batch-to-batch variations of C3b or the sensor chip
surfaces. Onlymeasurementsmade on the same chip and in the
same experiment can be meaningfully compared.
Wemutated anotherCCP1 residue (R53H) inCFHand com-
pared the consequences with those reported for R53H in the
autonomously functional CFH 1–4 fragment (41, 60). We
found (Fig. 6) (i) nearly normal C3b-binding affinity of R53H-
CFH; (ii) severalfold diminished complement-regulatory func-
tions of R53H-CFHon ES; and (iii) negative impacts of R53Hon
the DAA of CFH on an SPR surface. Encouragingly, these
benchmark results closely parallel those obtained for R53H-
CFH 1–4.
Such functional deficiencies are consistent with R53H caus-
ing aHUS (29), although it should be borne in mind that
patients are heterozygous, and serum concentrations of CFH
are 1–2 M (61). Moreover, 250 nM R53H-CFH had wild type–
like protective activity in the CFH-reconstituted Es hemolysis
assay (Fig. 4). To circumvent a potential anomaly of this assay,
that fluid-phase C3 depletion arises from lack of control by
R53H, we included along with R53H-CFH equimolar
amounts of I62-CFH or LA-CFH. I62-CFH regulates com-
plement in fluid phase and on surfaces; LA-CFH regulates
complement in fluid-phase only (see below). The 1:1 I62-
CFH/R53H-CFH combination, crudely emulating the sce-
nario in heterozygous patients, was also protective in our
assay because adequate I62-CFHwas present to achieve both
fluid-phase and on-surface regulation. Conversely, the 1:1
LA-CFH/R53-CFH was not protective, demonstrating that
250 nM R53-CFH could not protect ES from hemolysis if C3 is
present in the fluid phase.
Whereas easily prepared N-terminal truncation fragments,
such asCFH1–4, serve as a goodmodel for full-lengthCFH, the
equivalent claim cannot be made for C-terminal fragments.
More than 30 substitutions in CCPs 19 and 20 have been linked
Table 2
Decay-accelerating and cofactor activities on sheep erythrocytes
Experiment CA IC50 (nM)a
Effect of the variation
(or of PspCN)b DAA IC50 (nM)a
Effect of the variation
(or of PspCN)b
I62-CFH versus 8.00 0.33 1.19 0.12 1.35 0.10 0.94 0.11
V62-CFH 9.50 0.57 1.27 0.05
I62-CFH versus 8.00 0.33 (0.48 0.03) 1.77 0.05 (0.86 0.05)
I62-CFH PspCN 3.82 0.06 1.52 0.05
I62-CFH versus 17.5 0.8 2.44 0.26 1.41 0.44 4.72 0.32
R53H-CFH 42.7 2.5 6.65 0.25
R53H-CFH versus 42.7 2.5 (0.40 0.04) 6.68 0.6 (0.91 0.15)
R53H-CFH PsPCN 17.2 0.6 6.06 0.05
I62-CFH versus 12.0 0.8 40 1.33 0.09 8.06 1.31
D1119G-CFH 500 10.7 1.05
D1119G-CFH versus 500 9.21 0.54 (1.24 0.15)
D1119G-CFH PsPCN 500 11.5 0.7
I62-CFH versus 17.5 2.6 3.63 1.35 1.59 0.06 1.83 0.14
LA-CFH 63.4 14 2.92 0.12
LA-CFH versus 63.4 14 (0.75 0.38) 2.23 0.16 (0.87 0.14)
LA-CFH PsPCN 47.5 13 1.94 0.17
a Shown are the S.E. values for the fits of the data from each experiment.
b The ratio of either IC50 for the variant/IC50 for I62-CFH or (in parentheses) IC50 for CFH with PSPCN/IC50 for CFH without PspCN.
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to aHUS (31). Cross-linking and other evidence suggests that
theC-terminal CCPs ofCFHmodulate the activities carried out
by the N-terminal modules of the same molecule (8, 50). Thus,
the use of full-lengthCFH is essential to characterize functional
consequences of mutations in CCPs 19 and 20. Aspartate 1119,
in CCP 19, is a key residue in the C-terminal C3d and C3b-
binding site of CFH (53, 62). In the CFH 19-20 context, an
aHUS-linkedmutation, D1119G (29), severely reduced binding
to C3d and C3b (39, 53). Moreover, D1119G-CFH 19-20 was
40-fold less able than native-sequence CFH 19-20 to compete
with CFH for binding to C3b-coated ES (39). We previously
reported that full-length D1119G-CFH, despite having wild
type–like C3b-binding affinity and DAA activity on a foreign
SPR chip surface, did not protect ES from hemolysis (50).
Herein, we have taken this further by showing that D1119G
diminishes 10-fold the ability of CFH to accelerate decay of
Figure 6. Effects of R53H on CFH. A, an SPR experiment was performed in a manner similar to that shown in Fig. 2B to compare the affinity (for immobilized
C3b) of R53H-CFH (left) with that of I62-CFH (right; see experiment 1 in Table 1). This experiment was repeated with similar results (see experiment 2 in Table
1). B, an SPR-based assay of DAAwas performed in amanner similar to those shown in Fig. 3 except that 40 nM R53H-CFH or I62-CFH solutions were used. The
data shownare representative of twoexperiments.C, an ES-based assayofDAAwas carriedout in amanner similar to that shown in Fig. 5A.D, an ES-based assay
of CA was carried out in a manner similar to that shown in Fig. 5B. Triplicate measurements were made for each data point shown in C and D, and each
experiment was performed once. E, in an ES-surface assay (see Fig. 5A), PspCN (mixed 2:1 with R53-CFH) does not restore DAA to R53-CFH. F, in an ES-surface
assay (see Fig. 5B), PspCN at a 2:1 ratio with R53-CFH enhances its CA. For C–F, the mean and S.D. (error bars) of triplicate measurements are plotted, and
sigmoidal curves were fitted using SigmaPlot. Each graph is representative of two experiments.
Figure 7. On erythrocytes, D1119G-CFH has a greater effect on CA than DAA. In assays similar to the one used to generate Fig. 5 (A and B), D1119G
decreased the DAA of CFH on ES (A) and devastated CA on ES (B). C, PspCN (mixed 2:1 with D1119G-CFH) had little effect on the DAA of D1119G-CFHmeasured
on ES. D, PspCN (mixed 2:1 with D1119G-CFH) had a small effect on the very low CA of D1119G-CFH measured on ES. Mean and S.D. (error bars) of triplicate
measurements are plotted, and sigmoidal curves were fitted using SigmaPlot. Each graph is representative of two experiments.
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C3bBb assembled on ES. The effect of D1119G on the CA of
CFH, in the ES context, is still greater.
We further explored this theme through studies of the
aHUS-linked double mutation in CCP 20 of CFH correspond-
ing to a gene conversion with CFHR-1 (i.e. S1191L/V1197A)
(63). The crystal structure of S1191L-CFH 19-20 bound to C3d
is barely distinguishable from that of the wild-type CFH-19-
20–C3d complex (42). Conversely, LA-CFH 19-20 failed to
bind C3b-decorated ES (39). Subsequently, Ser-1191 and Val-
1197 were shown to contribute to the primary SA-binding site
in the CFH molecule (54). Here, we found that LA-CFH was
significantly poorer than wild-type CFH at protecting ES from
hemolysis by CFH-depleted normal human serum (Fig. 4). A
similar result (see above) was obtained using a 1:1 mixture of
LA-CFH and R53-CFH, yet in SPR experiments, the S1191L/
V1197A substitutions had little impact on binding of CFH to
C3b. Moreover, these mutations had only a small effect on
C3bBb-DAA whether C3bBb was assembled on an SPR chip
surface or, surprisingly, on the surrogate host surface of ES (Fig.
8). Conversely, LA-CFHwas significantly deficient in CA on ES
cells. This distinction betweenDAA andCA, also seen, albeit to
a lesser extent, in D1119G, is discussed further below.
PspCN binds plasma CFH tightly, enhancing its binding to
C3b and strongly increasing its affinity for C3d. The C3b/
C3d(g)-binding and self-recognition site in CCPs 19 and 20 of
CFH becomes exposed upon binding PspCN (50), perhaps
emulating what happens when CFH binds to a self-surface.
Herein, PspCN enhanced the affinities for C3b on an SPR chip,
of recombinant I62-CFH, V62-CFH, R53H-CFH, and, to a
lesser degree, LA-CFH (Table 1). PspCN also increased, to
roughly equal extents, the DAA of I62-CFH and V62-CFH on
an SPR chip (Fig. 3). In contrast, PspCN did not increase the
DAA of I62-CFH on C3bBb-decorated ES, and there was a sim-
ilar lack of responsiveness to PspCN from R53H-CFH,
D1119G-CFH, and LA-CFH DAA in the ES context (Table 2).
The discrepancy between the two assays probably reflects the
different surfaces employed: SA-bearing and self-like in the
case of ES and foreign in the case of SPR. In contrast with its
effects on ES-surface DAA, PspCN significantly enhanced the
CA of I62-CFH on C3b-loaded ES. It likewise had a positive
effect, in this context, on the CA of R53H-CFH, and it even
partially rescued the CA of LA-CFH (Fig. 8). This difference
between the responsiveness to PspCN of DAA and CA on ES
echoes differences between the impacts, on DAA (small) and
CA (larger), of the C-terminal mutations S1191L/V1197A and,
to a less pronounced extent, D1119G (Table 2).
Both DAA and CA reside in CFH CCPs 1–4 and can act in a
concerted manner, but each involves a distinct sequence of
events (Fig. 1). To accelerate C3bBb decay, CFHprobably binds
both the surface-attached C3b and the Bb (64) components of
C3bBb, whereupon it acts catalytically to dissociate C3bBb into
C3b and Bb. Following release of Bb, surface-tethered C3b
retains affinity for CFH because both binding sites on C3b,
engaged by CFHCCPs 1–4 and CCPs 19 and 20, remain intact,
as do interactions between CCP 20 and SA on the surface. The
CFHmolecule must subsequently dissociate from C3b to cata-
lyze another C3bBb decay event. As a cofactor, CFH binds to
surface-attached C3b and recruits CFI (65). Subsequent cleav-
age of C3b to iC3b destroys its binding site for CFH CCPs 1–4
(66). Importantly, the binding site on iC3b used byCCPs 19 and
20, along with the interaction between CCP 20 and SA, is not
affected. The presence of the product, iC3b or C3d(g), on an
SA-decorated surface thus creates the possibility of retaining or
enriching CFH on that surface by binding to the CFH C termi-
nus. Thus retained, these CFH molecules could utilize their
CCPs 1–4 to act as a cofactor on nearby C3b molecules. In
short, complete detachment and reattachment ofCFH from the
surface is likely between cycles of DAA, but in the case of CA,
CFHcan cycle between iC3b(C3d)-bound, iC3b(Cd)-plus-C3b-
bound, and C3b-bound forms, without leaving the surface.
The results obtained here for disease-linked C-terminal
mutants on ES surfaces support this line of reasoning because
they show that retention of CFH on a surface via its CCPs 19
and 20 is more important for CA than for DAA. Our results
with PspCN likewise support this reasoning because they con-
firm that the PspCN-induced increase in access to the surface-
engaging C-terminal modules has little effect on DAA but a
positive effect on CA.
To summarize, our results show that acceleration of C3bBb
decay on a hostlike surface is not very responsive to the pres-
ence or the absence (as tested by mutagenesis (Fig. 8C)) or the
availability or unavailability (tested by the inclusion or not of
PspCN (Fig. 8E)) of the self-recognition site in CCPs 19 and 20.
On the other hand, CA (for CFI onC3b bound to ES) is sensitive
to the presence or absence (mutagenesis) of the self-recognition
site (Fig. 8D) and its availability as enhanced by PspCN (Fig. 8F).
Soluble PspCN has a protective effect on ER in hemolysis
assays (Fig. 4). This was observed previously and is consistent
with bacterially displayed PspC preventing C3b amplification
on themicrobial surface. PspCNalso partially rescued function-
ally deficient LA-CFH in an ES hemolysis protection assay. These
aremore complex assays (comparedwith the individual CAA and
DAAassays)and less straightforwardto interpret.Nonetheless,we
infer thatPspCNcanwork as aprotector of self-surfacesmainly by
enhancing CFHCAon these surfaces, and this suggests new ther-
apeutic strategies based on CFH activators.
Experimental procedures
Preparation of proteins
Human CFHwas either purchased fromComplement Tech-
nologies or purified from pooled plasma (TCS Biosciences
Figure 8. Effects of S1191L/V1197A on CFH. A, an SPR experiment was performed in a manner similar to that shown in Fig. 2B to compare the affinity (for
immobilized C3b) of LA-CFH (left) with that of I62-CFH (right; see experiment 1 in Table 1). This experiment was repeated with similar results (see experiment
2 in Table 1).B, an SPR-based assay of theDAAof LA-CFHwasperformed in amanner similar to those shown in Fig. 3 except that 40nMCFH solutionswere used.
The data shown are representative of two experiments. C, an ES-based assay of DAAwas carried out in amanner similar to that shown in Fig. 5A.D, an ES-based
assay of CA was carried out in a manner similar to that shown in Fig. 5B. E, in an ES-surface assay (see Fig. 5A), PspCN (2:1 to LA-CFH) does not restore any DAA
to LA-CFH. F, conversely, in an ES-surface assay (see Fig. 5B), PspCN (2:1 to LA-CFH) significantly enhanced the CA of LA-CFH. For C–F, mean and S.D. (error bars)
of triplicate measurements are plotted, and sigmoidal curves were fitted using SigmaPlot. Each graph is representative of two experiments.
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Ltd.). Other plasma-derived human complement proteins
(CFB, CFD, CFI, C3b, and C3d) and CFH-depleted normal
human serum (Complement Technologies) were stored as
recommended by the supplier and used without further
purification.
Recombinant human CFH, corresponding to allotypic vari-
ant, Val-62, Tyr-402, Glu-936 (V62-CFH), was produced and
purified, following treatment with EndoHf to trim N-glycans
to GlcNAc residues, as described (36). Preparation of the
D1119G-CFHmutant (on a Val-62 background) was described
previously (50). Similar strategies were used to produce variant
Ile-62, Tyr-402, Asp-936 (I62-CFH) along with R53H-CFH
and S1191L/V1197A-CFH on the Ile-62 background. In brief,
expression-optimized DNA encoding the target protein se-
quence was synthesized (GeneArt-Life Technologies) and sub-
cloned into Pichia pastoris expression vector pPICZaB (Invit-
rogen). This was amplified in XL1 Blu Escherichia coli cells
(Agilent) and then used to transform the KM71H strain of
P. pastoris (Invitrogen). Single colonies grown on yeast-pep-
tone-dextran (YPD) agar plates with 300 g/ml Zeocin were
picked. The colony with the highest level of CFH production in
small-scale trials was used to inoculate a BioFlow 4500 (New
Brunswick Scientific) 10-liter fermenter. After a glycerol-fed
batch phase, protein production was induced by a 4-day meth-
anol/glycerol continuous feed. Secreted proteins were chro-
matographically purified (36) after enzymatic deglycosylation.
The protein PspCNwas produced as described (50). In brief,
a synthetic gene encoding positions 37–140 of PspC from D39
Streptococcus pneumoniaewas expression-optimized for E. coli
(GeneArt-Life Technologies). It was cloned into E. coli vector
pE-SumoPro-Kan (LifeSensors, Malvern, PA) and then
expressed in BL21 (DE3) E. coli cells (Lucigen). The resultant
N-terminally His6-SUMO-tagged protein was captured on
nickel-affinity resin, eluted with imidazole, and then further
purified by cation-exchange chromatography. The His6-
SUMO tag was cleaved from the fusion protein using ULP1, a
SUMO-specific protease, and removed by re-passing over the
nickel-affinity resin. Cleaved material was purified by size-ex-
clusion chromatography. Homogeneity was confirmed by SDS-
PAGE and MS.
Measurement of CFH and CFH–PspCN binding to C3b by SPR
Experiments were performed on a Biacore T200 at 25 °C as
described previously (43). Briefly, C3b was attached using stan-
dard amine coupling to flow cells of a Biacore C1 chip (GE
Healthcare). A second flow cell was used for background sub-
traction. A dilution series of CFH solutions in 10 mM HEPES
buffer, 150 mM NaCl, 0.05% (v/v) surfactant P20 (GE Health-
care), preincubated with or without a 2-fold molar excess of
PspCN, was injected for 150 s at 50 l/min and a dissociation
time of 600 s. The sensor chip was regenerated by three injec-
tions of 1 M NaCl. Data were analyzed using the Biacore Evalu-
ation software and a 1:1 steady-state binding model.
C3bBb decay-accelerating assay
Decay-accelerating activity was measured in an SPR-based
assay as described (67). In brief,500 RU of C3b were attached
to a Biacore CM5-sensor chip (GE Healthcare) using standard
amine coupling. Subsequently, C3bBb was assembled on the
chip by a 180-s 10-l/min injection of a solution containing 500
nM CFB and 50 nM CFD. Formation of C3bBb (150 RU) was
monitored, and then an initial dissociation phase (of 240-s
duration) allowed observation of intrinsic convertase decay (i.e.
a decline in RUs attributable to loss of Bb). Subsequently, CFH
or CFH–PspCN was injected (10 l/min for 180 s), allowing
observation of a further dissociation phase. The chipwas regen-
erated between cycles by a 30-s injection of 0.1 M CFH and
three 30-s injections of 1 M NaCl.
Preparation of cells for complement regulation assays
According to Tortajada et al. (22), ES in Alsever’s solution
(TCS Biosciences) were pelleted and resuspended three times
in complement-fixation diluent (C-FxD) (Oxoid, Thermo
Fisher Scientific). The washed cells, at 2% (w/v) in C-FxD, were
sensitized by incubation with anti-ES stroma antibody from
rabbit (Sigma) (diluted 1:4000 (v/v) in the C-FxD) for 30 min at
37 °C. Sensitized sheep erythrocytes (EAS) were washed three
times in C-FxD and then resuspended in C-FxD to a final cell
density of 2% (w/v). C3b was then deposited on the EAS surface
by adding one volume of 4% (v/v) CFB-deficient and CFH-de-
ficient normal human serum (BH-NHS) (22) containing 6
g/ml Ornithodoros moubata complement inhibitor (a gift
from Varleigh Immuno Pharmaceuticals) in C-FxD, followed
by a 20-min incubation at 37 °C. The C3b-coated EAS (EAS-
C3b) were washed three times in AP buffer (5 mM sodium bar-
bitone, pH 7.4, 150 mM NaCl, 7 mM MgCl2, 10 mM EGTA).
Finally, EAS-C3b cells were resuspended at 2% (v/v) in AP
buffer.
Cofactor assays on erythrocytes
Cofactor activity was determined by adding (in triplicate) 50
l from a dilution series of wild-type or mutant CFH solutions,
with or without PspCN at a 2:1 PspCN/CFH molar ratio, to 50
l of a 2% (w/v) suspension of EAS-C3b in AP buffer containing
2.5 g/ml CFI. After 15 min (25 °C) of C3b proteolysis, cells
were washed three times in 200 l of AP buffer and pelleted.
Washed cells were resuspended in 50 l of AP buffer in prepa-
ration for C3bBb formation as an indirect measure of surviving
C3b (22). To this end, C3bBb was formed by adding 50 l of a
solution containing 40 g/ml CFB and 0.2 g/ml CFD to 50 l
of the CFH-treated and CFI-treated EAS-C3b and incubating
for 15 min at 37 °C. Lysis was then used as a read-out of C3bBb
formed on cells. This part of the assay was performed by adding
BH-NHS to a final concentration of 4% (v/v) to the sus-
pended cells and incubating for 20 min at 37 °C. To quantify
lysis, cells were pelleted, and the absorbance (A420 nm) of the
supernatant was measured on aMultiskan Ascent Plate Reader
(Agilent). The no-lysis controls, for blank subtraction, con-
tained no CFB or CFD. Maximal lysis was determined by an
A420 measurement following the addition of PBS, instead of
CFH solution, to the EAS-C3b. Mean readings from experi-
ments performed in triplicate were calculated. Total protection
from lysis for each concentration of CFH was determined by
subtracting, from 1, the following: ((mean A420 for a particular
CFH sample)  (mean A420 for a no-lysis control sample))/
(A420 for a sample where PBS was used rather than CFH). This
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was then multiplied by 100. A sigmoidal curve was fitted using
SigmaPlot and employed to determine the concentration at
which CFH gave 50% protection from lysis (IC50).
Decay-accelerating activities on erythrocytes
For these assays, C3bBb was formed on EAS-C3b by adding
50l of AP buffer containing 40g/ml CFB and 0.2g/ml CFD
to 50 l of a cell suspension (22). After 15 min (37 °C), C3bBb
formation was stopped by the addition of PBS containing 250
M EDTA, pH 7.4, at a 1:20 dilution. Following the addition of
50 l from a dilution series of (wild-type or mutant) CFH solu-
tions (with or without PspCN at a 2:1 ratio) in PBS, C3bBb was
allowed to decay for 15 min (25 °C). The extent of lysis then
served as ameasure of remainingC3bBb, as described above. As
above, mean readings of experiments in triplicate were calcu-
lated. Total protection from lysis for each concentration of
CFHwas determined as above, and a sigmoidal curve was fitted
using SigmaPlot to determine the concentration at which CFH
gave 50% protection from lysis (IC50).
Hemolysis protection assays
For this 96-well plate assay (46), ES and ER (TCS Biosciences)
were prepared by washing three times with buffer E1 (20 mM
HEPES, 145 mM NaCl, 0.1% (w/v) gelatin (porcine skin; Fluka),
10 mM EDTA, pH 7.3) and then buffer E2 (20 mM HEPES, 145
mM NaCl, 0.1% (w/v) gelatin, 10 M EDTA, pH 7.3). A stock of
E was suspended in E2 at a density such that an A412 nM 
1.0–1.2 resulted following complete lysis in water. CFH-de-
pleted serum (H-NHS) was reconstituted with a stated, final
concentration (250 nM to 1.0 M) CFH, with or without PspCN
(at a 2:1 PspCN/CFH ratio), and then aliquots of varying size
were combined, to give various percentages of H-NHS/CFH,
with 5l ofE stock and buffer E2 to a final volumeof 45l. Lysis
was initiated by adding 5 l of 50 mM MgEGTA, pH 7.3. The
reaction was incubated (37 °C) for 30 min and then quenched
with 200 l of buffer E1. The plate was spun (1500	 g, 10 min,
4 °C) to pellet non-lysed cells, and then 100 l of supernatant
from eachwell was transferred to another 96-well plate forA412
measurements.
Author contributions—H. K. produced theCFHmutants and carried
out someof the assays; E. W. performed the erythrocyte-based assays
of CA andDAA; E. M. contributed to the production, and carried out
the SPR-based comparisons, of V62-CFH and I62-CFH; Y. Y. carried
out the hemolysis protection assays; K. M. designed experiments and
contributed towriting themanuscript; D. K. andA. R. helped to con-
ceive the study and contributed to the experimental design; A. P. H.
contributed to the experimental design and to the production and
purification of proteins; P. N. B. helped to conceive the study, con-
tributed to the experimental design, and wrote the manuscript.
Acknowledgments—We thank Dr. John White for performing P. pas-
toris fermentations, and we thank the staff at the University of Edin-
burgh Protein Production Facility, and Dr. Liz Blackburn in particu-
lar, for expert assistance in protein purification.
References
1. Walport, M. J. (2001) Complement: first of two parts.N. Engl. J. Med. 344,
1058–1066
2. Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J. D. (2010) Comple-
ment: a key system for immune surveillance and homeostasis.Nat. Immu-
nol. 11, 785–797
3. Lachmann, P. J. (2009) The amplification loop of the complement path-
ways. Adv. Immunol. 104, 115–149
4. Sahu, A., Kozel, T. R., and Pangburn, M. K. (1994) Specificity of the thio-
ester-containing reactive site of human C3 and its significance to comple-
ment activation. Biochem. J. 302, 429–436
5. Hourcade, D. E. (2006) The role of properdin in the assembly of the alter-
native pathway C3 convertases of complement. J. Biol. Chem. 281,
2128–2132
6. Schmidt, C. Q., Herbert, A. P., Hocking, H. G., Uhrı´n, D., and Barlow, P. N.
(2008) Translational mini-review series on complement factor H: struc-
tural and functional correlations for factor H. Clin. Exp. Immunol. 151,
14–24
7. Ferreira, V. P., Pangburn, M. K., and Corte´s, C. (2010) Complement con-
trol protein factor H: the good, the bad, and the inadequate.Mol. Immu-
nol. 47, 2187–2197
8. Makou, E., Herbert, A. P., and Barlow, P. N. (2013) Functional anatomy of
complement factor H. Biochemistry 52, 3949–3962
9. Stossel, T. P., Field, R. J., Gitlin, J. D., Alper, C. A., and Rosen, F. S. (1975)
The opsonic fragment of the third component of human complement
(C3). J. Exp. Med. 141, 1329–1347
10. Meri, S., and Pangburn, M. K. (1990) Discrimination between activators
and nonactivators of the alternative pathway of complement: regulation
via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci.
U.S.A. 87, 3982–3986
11. Kirkitadze, M. D., and Barlow, P. N. (2001) Structure and flexibility of the
multiple domain proteins that regulate complement activation. Immunol.
Rev. 180, 146–161
12. Zipfel, P. F., Jokiranta, T. S., Hellwage, J., Koistinen, V., andMeri, S. (1999)
The factor H protein family. Immunopharmacology 42, 53–60
13. Goicoechea de Jorge, E., Caesar, J. J., Malik, T. H., Patel, M., Colledge, M.,
Johnson, S., Hakobyan, S., Morgan, B. P., Harris, C. L., Pickering, M. C.,
and Lea, S. M. (2013) Dimerization of complement factor H-related pro-
teins modulates complement activation in vivo. Proc. Natl. Acad. Sci.
U.S.A. 110, 4685–4690
14. Jo´zsi,M., Tortajada, A., Uzonyi, B., Goicoechea de Jorge, E., andRodrı´guez
de Co´rdoba, S. (2015) Factor H-related proteins determine complement-
activating surfaces. Trends Immunol. 36, 374–384
15. Richards, A., Kavanagh, D., and Atkinson, J. P. (2007) Inherited comple-
ment regulatory protein deficiency predisposes to human disease in acute
injury and chronic inflammatory states: the examples of vascular damage
in atypical hemolytic uremic syndrome and debris accumulation in age-
related macular degeneration. Adv. Immunol. 96, 141–177
16. de Co´rdoba, S. R., and de Jorge, E. G. (2008) Translational mini-review
series on complement factor H: genetics and disease associations of hu-
man complement factor H. Clin. Exp. Immunol. 151, 1–13
17. Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J. Y., Sackler, R. S., Haynes, C.,
Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., Bracken,
M. B., Ferris, F. L., Ott, J., Barnstable, C., and Hoh, J. (2005) Complement
factor H polymorphism in age-relatedmacular degeneration. Science 308,
385–389
18. Edwards, A. O., Ritter, R., 3rd, Abel, K. J., Manning, A., Panhuysen, C., and
Farrer, L. A. (2005) Complement factor H polymorphism and age-related
macular degeneration. Science 308, 421–424
19. Haines, J. L., Hauser,M. A., Schmidt, S., Scott,W. K., Olson, L.M., Gallins,
P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., Schnetz-
Boutaud, N., Agarwal, A., Postel, E. A., and Pericak-Vance, M. A. (2005)
Complement factor H variant increases the risk of age-related macular
degeneration. Science 308, 419–421
20. Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber,
A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D.,
Gehrs, K. M., Smith, R. J., Silvestri, G., Russell, S. R., Klaver, C. C., Barba-
zetto, I., et al. (2005) A common haplotype in the complement regulatory
gene factor H (HF1/CFH) predisposes individuals to age-related macular
degeneration. Proc. Natl. Acad. Sci. U.S.A. 102, 7227–7232
Disease-linkedmutations in recombinant factor H
13358 J. Biol. Chem. (2017) 292(32) 13345–13360
 at U
niversity of Edinburgh on Septem
ber 5, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
21. Barbour, T. D., Ruseva, M. M., and Pickering, M. C. (2016) Update on C3
glomerulopathy. Nephrol. Dial. Transplant. 31, 717–725
22. Tortajada, A., Montes, T., Martı´nez-Barricarte, R., Morgan, B. P., Harris,
C. L., and de Co´rdoba, S. R. (2009) The disease-protective complement
factor H allotypic variant Ile62 shows increased binding affinity for C3b
and enhanced cofactor activity. Hum. Mol. Genet. 18, 3452–3461
23. Hughes, A. E., Orr, N., Esfandiary, H., Diaz-Torres, M., Goodship, T., and
Chakravarthy, U. (2006) A common CFH haplotype, with deletion of
CFHR1 and CFHR3, is associated with lower risk of age-related macular
degeneration. Nat. Genet. 38, 1173–1177
24. Jo´zsi, M., Licht, C., Strobel, S., Zipfel, S. L., Richter, H., Heinen, S., Zipfel,
P. F., and Skerka, C. (2008) Factor H autoantibodies in atypical hemolytic
uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111,
1512–1514
25. Smith, R. J., Harris, C. L., and Pickering, M. C. (2011) Dense deposit dis-
ease.Mol. Immunol. 48, 1604–1610
26. Moore, I., Strain, L., Pappworth, I., Kavanagh, D., Barlow, P. N., Herbert,
A. P., Schmidt, C. Q., Staniforth, S. J., Holmes, L. V.,Ward, R., Morgan, L.,
Goodship, T. H., and Marchbank, K. J. (2010) Association of factor H
autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mu-
tations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic
uremic syndrome. Blood 115, 379–387
27. Noris, M., and Remuzzi, G. (2009) Atypical hemolytic-uremic syndrome.
N. Engl. J. Med. 361, 1676–1687
28. Jo´zsi,M., Heinen, S., Hartmann, A., Ostrowicz, C.W., Ha¨lbich, S., Richter,
H., Kunert, A., Licht, C., Saunders, R. E., Perkins, S. J., Zipfel, P. F., and
Skerka, C. (2006) Factor H and atypical hemolytic uremic syndrome: mu-
tations in the C-terminus cause structural changes and defective recogni-
tion functions. J. Am. Soc. Nephrol. 17, 170–177
29. Saunders, R. E., Abarrategui-Garrido, C., Fre´meaux-Bacchi, V., Goi-
coechea de Jorge, E., Goodship, T. H., Lo´pez Trascasa, M., Noris, M.,
Ponce Castro, I. M., Remuzzi, G., Rodrı´guez de Cordoba, S., Sa´nchez-
Corral, P., Skerka, C., Zipfel, P. F., and Perkins, S. J. (2007) The interactive
Factor H-atypical hemolytic uremic syndrome mutation database and
website: update and integration of membrane cofactor protein and Factor
I mutations with structural models. Hum. Mutat. 28, 222–234
30. Kavanagh, D., andGoodship, T. (2010) Genetics and complement in atyp-
ical HUS. Pediatr. Nephrol. 25, 2431–2442
31. Kavanagh,D., Goodship, T.H., andRichards, A. (2013)Atypical hemolytic
uremic syndrome. Semin. Nephrol. 33, 508–530
32. Rodrı´guez de Co´rdoba, S. (2010) aHUS: a disorder with many risk factors.
Blood 115, 158–160
33. Sa´nchez-Corral, P., Pe´rez-Caballero, D., Huarte, O., Simckes, A. M., Goi-
coechea, E., Lo´pez-Trascasa, M., and de Co´rdoba, S. R. (2002) Structural
and functional characterization of factor H mutations associated with
atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 71, 1285–1295
34. Sharma, A. K., and Pangburn, M. K. (1994) Biologically active recombi-
nant human complement factor H: synthesis and secretion by the bacu-
lovirus system. Gene 143, 301–302
35. Bu¨ttner-Mainik, A., Parsons, J., Je´roˆme, H., Hartmann, A., Lamer, S.,
Schaaf, A., Schlosser, A., Zipfel, P. F., Reski, R., and Decker, E. L. (2011)
Production of biologically active recombinant human factor H in
Physcomitrella. Plant Biotechnol. J. 9, 373–383
36. Schmidt, C. Q., Slingsby, F. C., Richards, A., and Barlow, P. N. (2011)
Production of biologically active complement factor H in therapeutically
useful quantities. Protein Expr. Purif. 76, 254–263
37. Ferreira, V. P., Herbert, A. P., Hocking, H. G., Barlow, P. N., and Pangburn,
M. K. (2006) Critical role of the C-terminal domains of factor H in regu-
lating complement activation at cell surfaces. J. Immunol. 177,
6308–6316
38. Hocking, H. G., Herbert, A. P., Kavanagh, D., Soares, D. C., Ferreira, V. P.,
Pangburn, M. K., Uhrı´n, D., and Barlow, P. N. (2008) Structure of the
N-terminal region of complement factor H and conformational implica-
tions of disease-linked sequence variations. J. Biol. Chem. 283, 9475–9487
39. Ferreira, V. P., Herbert, A. P., Corte´s, C., McKee, K. A., Blaum, B. S.,
Esswein, S. T., Uhrı´n, D., Barlow, P. N., Pangburn,M. K., andKavanagh, D.
(2009) The binding of factor H to a complex of physiological polyanions
andC3b on cells is impaired in atypical hemolytic uremic syndrome. J. Im-
munol. 182, 7009–7018
40. Lehtinen, M. J., Rops, A. L., Isenman, D. E., van der Vlag, J., and Jokiranta,
T. S. (2009)Mutations of factorH impair regulation of surface-boundC3b
by three mechanisms in atypical hemolytic uremic syndrome. J. Biol.
Chem. 284, 15650–15658
41. Pechtl, I. C., Kavanagh, D., McIntosh, N., Harris, C. L., and Barlow, P. N.
(2011) Disease-associated N-terminal complement factor H mutations
perturb cofactor and decay-accelerating activities. J. Biol. Chem. 286,
11082–11090
42. Herbert, A. P., Kavanagh, D., Johansson, C., Morgan, H. P., Blaum, B. S.,
Hannan, J. P., Barlow, P.N., andUhrı´n, D. (2012) Structural and functional
characterization of the product of disease-related factor H gene conver-
sion. Biochemistry 51, 1874–1884
43. Schmidt, C. Q., Herbert, A. P., Kavanagh, D., Gandy, C., Fenton, C. J.,
Blaum, B. S., Lyon, M., Uhrı´n, D., and Barlow, P. N. (2008) A new map of
glycosaminoglycan and C3b binding sites on factor H. J. Immunol. 181,
2610–2619
44. Gordon, D. L., Kaufman, R. M., Blackmore, T. K., Kwong, J., and Lublin,
D. M. (1995) Identification of complement regulatory domains in human
factor H. J. Immunol. 155, 348–356
45. Ku¨hn, S., and Zipfel, P. F. (1996) Mapping of the domains required for
decay acceleration activity of the human factor H-like protein 1 and factor
H. Eur. J. Immunol. 26, 2383–2387
46. Pangburn, M. K. (2002) Cutting edge: localization of the host recognition
functions of complement factor H at the carboxyl-terminal: implications
for hemolytic uremic syndrome. J. Immunol. 169, 4702–4706
47. Jokiranta, T. S., Hellwage, J., Koistinen, V., Zipfel, P. F., andMeri, S. (2000)
Each of the three binding sites on complement factor H interacts with a
distinct site on C3b. J. Biol. Chem. 275, 27657–27662
48. Oppermann, M., Manuelian, T., Jo´zsi, M., Brandt, E., Jokiranta, T. S., Hei-
nen, S., Meri, S., Skerka, C., Go¨tze, O., and Zipfel, P. F. (2006) The C-ter-
minus of complement regulator Factor H mediates target recognition:
evidence for a compact conformation of the native protein. Clin. Exp.
Immunol. 144, 342–352
49. Schmidt, C. Q., Bai, H., Lin, Z., Risitano, A. M., Barlow, P. N., Ricklin, D.,
and Lambris, J. D. (2013) Rational engineering of a minimized immune
inhibitor with unique triple-targeting properties. J. Immunol. 190,
5712–5721
50. Herbert, A. P.,Makou, E., Chen, Z. A., Kerr, H., Richards, A., Rappsilber, J.,
and Barlow, P. N. (2015) Complement evasion mediated by enhancement
of captured factor H: implications for protection of self-surfaces from
complement. J. Immunol. 195, 4986–4998
51. Barlow, P. N., Baron,M., Norman, D. G., Day, A. J.,Willis, A. C., Sim, R. B.,
and Campbell, I. D. (1991) Secondary structure of a complement control
proteinmodule by two-dimensional 1HNMR.Biochemistry 30, 997–1004
52. Dave, S., Brooks-Walter, A., Pangburn, M. K., and McDaniel, L. S. (2001)
PspC, a pneumococcal surface protein, binds human factor H. Infect. Im-
mun. 69, 3435–3437
53. Morgan, H. P., Schmidt, C. Q., Guariento, M., Blaum, B. S., Gillespie, D.,
Herbert, A. P., Kavanagh, D., Mertens, H. D., Svergun, D. I., Johansson,
C.M., Uhrı´n, D., Barlow, P.N., andHannan, J. P. (2011) Structural basis for
engagement by complement factor H of C3b on a self surface.Nat. Struct.
Mol. Biol. 18, 463–470
54. Blaum, B. S., Hannan, J. P., Herbert, A. P., Kavanagh, D., Uhrı´n, D., and
Stehle, T. (2015) Structural basis for sialic acid-mediated self-recognition
by complement factor H. Nat. Chem. Biol. 11, 77–82
55. Michelfelder, S., Parsons, J., Bohlender, L. L., Hoernstein, S. N., Nieder-
kru¨ger, H., Busch, A., Krieghoff, N., Koch, J., Fode, B., Schaaf, A.,
Frischmuth, T., Pohl, M., Zipfel, P. F., Reski, R., Decker, E. L., and Ha¨ffner,
K. (2017) Moss-produced, glycosylation-optimized human factor H for
therapeutic application in complement disorders. J. Am. Soc. Nephrol. 28,
1462–1474
56. Davila, S., Wright, V. J., Khor, C. C., Sim, K. S., Binder, A., Breunis, W. B.,
Inwald, D., Nadel, S., Betts, H., Carrol, E. D., de Groot, R., Hermans, P.W.,
Hazelzet, J., Emonts,M., Lim, C. C., et al. (2010)Genome-wide association
study identifies variants in the CFH region associated with host suscepti-
bility to meningococcal disease. Nat. Genet. 42, 772–776
Disease-linkedmutations in recombinant factor H
J. Biol. Chem. (2017) 292(32) 13345–13360 13359
 at U
niversity of Edinburgh on Septem
ber 5, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
57. Hellwig, M., and Henle, T. (2014) Baking, ageing, diabetes: a short history
of the Maillard reaction. Angew. Chem. 53, 10316–10329
58. Fenaille, F., LeMignon,M., Groseil, C., Ramon, C., Riande´, S., Siret, L., and
Bihoreau, N. (2007) Site-specific N-glycan characterization of human
complement factor H. Glycobiology 17, 932–944
59. Harris, C. L., Heurich, M., Rodriguez de Cordoba, S., and Morgan, B. P.
(2012) The complotype: dictating risk for inflammation and infection.
Trends Immunol. 33, 513–521
60. Wong, E. K., Anderson, H. E., Herbert, A. P., Challis, R. C., Brown, P., Reis,
G. S., Tellez, J. O., Strain, L., Fluck, N., Humphrey, A., Macleod, A., Rich-
ards, A., Ahlert, D., Santibanez-Koref, M., Barlow, P. N., et al. (2014)
Characterization of a factorHmutation that perturbs the alternative path-
way of complement in a family with membranoproliferative GN. J. Am.
Soc. Nephrol. 25, 2425–2433
61. Hakobyan, S., Harris, C. L., Tortajada, A., Goicochea de Jorge, E., Garcı´a-
Layana, A., Ferna´ndez-Robredo, P., Rodrı´guez de Co´rdoba, S., and Mor-
gan, B. P. (2008) Measurement of factor H variants in plasma using vari-
ant-specific monoclonal antibodies: application to assessing risk of age-
relatedmacular degeneration. Invest. Ophthalmol. Vis. Sci. 49, 1983–1990
62. Kajander, T., Lehtinen, M. J., Hyva¨rinen, S., Bhattacharjee, A., Leung, E.,
Isenman, D. E., Meri, S., Goldman, A., and Jokiranta, T. S. (2011) Dual
interaction of factor Hwith C3d and glycosaminoglycans in host-nonhost
discrimination by complement. Proc. Natl. Acad. Sci. U.S.A. 108,
2897–2902
63. Heinen, S., Sanchez-Corral, P., Jackson, M. S., Strain, L., Goodship, J. A.,
Kemp, E. J., Skerka, C., Jokiranta, T. S., Meyers, K., Wagner, E., Robitaille,
P., Esparza-Gordillo, J., Rodriguez de Cordoba, S., Zipfel, P. F., and Good-
ship, T. H. (2006)De novo gene conversion in the RCA gene cluster (1q32)
causes mutations in complement factor H associated with atypical hemo-
lytic uremic syndrome. Hum. Mutat. 27, 292–293
64. Hourcade, D. E., Mitchell, L. M., and Medof, M. E. (1999) Decay acceler-
ation of the complement alternative pathway C3 convertase. Immunop-
harmacology 42, 167–173
65. Roversi, P., Johnson, S., Caesar, J. J., McLean, F., Leath, K. J., Tsiftsoglou,
S. A., Morgan, B. P., Harris, C. L., Sim, R. B., and Lea, S. M. (2011) Struc-
tural basis for complement factor I control and its disease-associated se-
quence polymorphisms. Proc. Natl. Acad. Sci. U.S.A. 108, 12839–12844
66. Wu, J., Wu, Y. Q., Ricklin, D., Janssen, B. J., Lambris, J. D., and Gros, P.
(2009) Structure of complement fragment C3b-factor H and implications
for host protection by complement regulators. Nat. Immunol. 10,
728–733
67. Harris, C. L., Abbott, R. J., Smith, R. A.,Morgan, B. P., and Lea, S.M. (2005)
Molecular dissection of interactions between components of the alterna-
tive pathway of complement and decay accelerating factor (CD55). J. Biol.
Chem. 280, 2569–2578
Disease-linkedmutations in recombinant factor H
13360 J. Biol. Chem. (2017) 292(32) 13345–13360
 at U
niversity of Edinburgh on Septem
ber 5, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Kavanagh, Anna Richards, Andrew P. Herbert and Paul N. Barlow
Heather Kerr, Edwin Wong, Elisavet Makou, Yi Yang, Kevin Marchbank, David
selective regulation of complement activation−self-surface
 Disease-linked mutations in factor H reveal pivotal role of cofactor activity in
doi: 10.1074/jbc.M117.795088 originally published online June 21, 2017
2017, 292:13345-13360.J. Biol. Chem. 
  
 10.1074/jbc.M117.795088Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/292/32/13345.full.html#ref-list-1
This article cites 67 references, 31 of which can be accessed free at
 at U
niversity of Edinburgh on Septem
ber 5, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
